相关实验视频
Updated: Jan 23, 2026
11:29
A Modified Method for Heterotopic Mouse Heart Transplantion
Published on: June 23, 2014
13.1K
随着LVAD支持和在晚期心力衰竭中心脏移植后,生活质量的长期变化
Kiyonori Kobayashi1,2, Tomo Yoshizumi3, Yoshiyuki Tokuda3
1Department of Rehabilitation, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8560, Japan. kobayashi.kiyonori.t8@f.mail.nagoya-u.ac.jp.
BMC cardiovascular disorders
|January 21, 2026
概括
桥梁到移植左心室辅助器件 (BTT-LVAD) 治疗和心脏移植显著改善晚期心力衰竭患者的身体生活质量 (QOL). 心理QOL保持稳定,强调需要持续的心理支持.
科学领域:
- 心脏病学 心脏病学
- 移植医学 移植医学
- 生活质量研究 研究 生命质量研究
背景情况:
- 生活质量 (QOL) 是接受左心室辅助器件 (LVAD) 治疗或心脏移植的高级心力衰竭患者的关键目标.
- 日本的长期QOL结果是不确定的,因为由于供体短缺,需要长期的LVAD支持.
研究的目的:
- 评估在LVAD植入和心脏移植之前和之后的纵向QOL变化.
- 调查这些患者的QOL和身体功能之间的关系.
主要方法:
- 分析了19名接受LVAD植入和随后心脏移植的患者队列.
- 在基线,在LVAD支持期间和移植后使用简式-36 (SF-36) 测量QOL.
- 身体功能通过握力,腿部力量,6分钟步行距离 (6MWD) 和峰值氧气吸收来评估.
主要成果:
- 基线QOL显示身体受损 (PCS 22.9),但保持精神 (MCS 49.1) 领域.
- 支持LVAD显著改善了PCS (40.1,p=0.008),而MCS保持稳定 (52.4).
- 心脏移植进一步改善了PCS (46.3,p=0.006) 与持续稳定的MCS (53.3).
结论:
- 桥梁到移植的LVAD和心脏移植显著提高了晚期心力衰竭中的身体质量.
- 心理QOL长期保持稳定,这表明持续的心理负担需要全面的护理.
- 身体功能测量结果显示,与移植后的PCS无显著的正相关性.
相关概念视频
01:29Heart Failure II: Pathophysiology
790
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
790
01:17Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
01:27Heart Failure I: Introduction
729
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
729
01:22Heart Failure VI: Adjunct Therapies
278
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
278
01:22Heart Failure Drugs: Diuretics
825
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
825
01:30Heart Failure V: Medical Management
227
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227